EZH2 knockdown in mouse models of cancer or targeting EZH2 with specific inhibitors allowed restoration of MHC-I expression in melanoma, B cell lymphoma and lung cancer [43,44,112,113]. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.